AI Article Synopsis
- Managing anticoagulant therapy in patients with conditions like kidney disease, liver disease, and obesity involves specific challenges due to altered drug clearance, metabolism, and distribution.
- Renal impairment can impact how drugs are eliminated from the body, while liver disease changes how drugs are processed and can affect coagulation.
- A one-size-fits-all approach doesn't work; personalized treatment plans are crucial for safely balancing the risks and benefits in patients with increased bleeding risk or thrombocytopenia.
Article Abstract
Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.61409/V05240367 | DOI Listing |
Publication Analysis
Top Keywords
liver disease
8
increased bleeding
8
bleeding risk
8
risk thrombocytopenia
8
[not available]
4
available] managing
4
managing anticoagulant
4
anticoagulant therapy
4
therapy patients
4
patients comorbidities
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!